Saturna Capital’s Anavex Life Sciences AVXL Stock Holding History

Saturna Capital’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-12,540	Closed	-$82.1K	–	175
2023 Q3	$82.1K	Hold	12,540	–	–	﹤0.01%	173
2023 Q2	$102K	Sell	12,540 -5,410	-30%	-$46.4K	﹤0.01%	164
2023 Q1	$154K	Buy	17,950 +5,650	+46%	+$56.4K	﹤0.01%	156
2022 Q4	$114K	Hold	12,300	–	–	﹤0.01%	149
2022 Q3	$127K	Hold	12,300	–	–	﹤0.01%	154
2022 Q2	$123K	Hold	12,300	–	–	﹤0.01%	158
2022 Q1	$151K	Sell	12,300 -1,500	-11%	-$18.4K	﹤0.01%	167
2021 Q4	$239K	Buy	13,800 +200	+1%	+$3.8K	﹤0.01%	159
2021 Q3	$244K	Buy	13,600 +500	+4%	+$9.95K	﹤0.01%	161
2021 Q2	$299K	Hold	13,100	–	–	0.01%	153
2021 Q1	$196K	Buy	+13,100	New	+$143K	﹤0.01%	162

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Saturna Capital's AVXL Position: Q4 2023 in Review

Saturna Capital sold out of Anavex Life Sciences (AVXL) in Q4 2023, closing a stake of 12,540 shares — an estimated $82.1K sold.

Saturna Capital first reported a position in AVXL in Q1 2021 and held it in 11 quarters. The position peaked at $299K in Q2 2021. 153 funds tracked by Wall St. Rank hold AVXL as of Q4 2023.

Saturna Capital reported no remaining Anavex Life Sciences position as of Q4 2023 after selling out during the quarter.
Saturna Capital sold 12,540 Anavex Life Sciences shares in Q4 2023, an estimated $82.1K.
Saturna Capital first reported a position in Anavex Life Sciences in Q1 2021 and held it in 11 quarters.
Saturna Capital's Anavex Life Sciences position peaked at $299K in Q2 2021.
153 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2023.

Based on Saturna Capital's 13F filing for Q4 2023, filed 6 Feb 2024.